ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Abemaciclib|DRUG: Hydroxychloroquine
Sponsor: Abramson Cancer Center at Penn Medicine